Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Argenica Therapeutics Ltd ( (AU:AGN) ).
Argenica Therapeutics Ltd announced the quotation of 352,345 ordinary fully paid securities on the ASX, following advice to list these shares, which were previously subject to voluntary escrow. This move potentially enhances the company’s market presence and liquidity, offering stakeholders increased opportunities for investment and engagement.
The most recent analyst rating on (AU:AGN) stock is a Buy with a A$1.14 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.
More about Argenica Therapeutics Ltd
Argenica Therapeutics Ltd operates in the biotechnology industry, focusing on developing therapeutic solutions. The company is engaged in advancing treatments for neurological conditions, aiming to improve patient outcomes in this specialized market.
Average Trading Volume: 94,515
Technical Sentiment Signal: Buy
See more insights into AGN stock on TipRanks’ Stock Analysis page.